Modified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP-Intolerant OSA Patients: A Clinical Evidence Review

Highlights

• The modified sleep apnea severity index (mSASI) integrates anatomical, clinical, and polysomnographic parameters, potentially enhancing cardiovascular risk stratification in OSA beyond apnea-hypopnea index (AHI) alone.
• CPAP-intolerant obstructive sleep apnea (OSA) patients undergoing surgical interventions show associations between higher mSASI scores and prevalent hypertension and elevated Framingham Risk Scores (FRS).
• Multivariable analyses affirm independent associations of mSASI and age with cardiovascular risk, although these associations attenuate when overlapping index components are excluded, underscoring complexity of composite risk tools.
• Current evidence supports cautious application of mSASI in clinical decision-making, highlighting the need for further prospective validation and analysis of incremental predictive value beyond traditional metrics.

Background

Obstructive sleep apnea (OSA) is a prevalent disorder characterized by recurrent upper airway collapse during sleep, causing intermittent hypoxia and sleep fragmentation. It is strongly associated with adverse cardiovascular (CV) outcomes including hypertension, coronary artery disease, stroke, and heart failure. Continuous positive airway pressure (CPAP) remains the first-line treatment but is limited by adherence challenges. For CPAP-intolerant patients, surgical options such as hypoglossal nerve stimulation, maxillomandibular advancement, or expansion sphincter pharyngoplasty provide alternative therapies.

Severity of OSA has traditionally been quantified using the apnea-hypopnea index (AHI), but this measure inadequately captures the multifactorial pathophysiology and symptom burden relevant to CV risk. The modified sleep apnea severity index (mSASI) represents a composite score incorporating airway anatomy, body mass index (BMI), polysomnographic severity, and clinical symptoms to stratify OSA severity from 1 (mild) to 3 (severe). This index aims to better reflect the clinical heterogeneity and prognostic implications of OSA, particularly for CV risk prediction.

Key Content

Development and Validation of the Modified Sleep Apnea Severity Index (mSASI)

The mSASI was developed with the intent of improving risk stratification by integrating objective anatomical and physiological parameters with patient-reported symptomatology. Early studies demonstrated its feasibility in characterizing OSA severity towards guiding individualized therapy. The index components typically include upper airway collapsibility features, BMI or weight, polysomnographic data such as AHI or oxygen desaturation indices, and clinical symptoms including daytime sleepiness measured by scales like the Epworth Sleepiness Scale.

A 2026 retrospective cohort study by Kaki et al. at a tertiary center analyzed 209 CPAP-intolerant OSA patients who underwent sleep surgery. This cohort included interventions such as hypoglossal nerve stimulation, maxillomandibular advancement, and expansion sphincter pharyngoplasty, reflective of common surgical approaches for OSA refractory to CPAP. Preoperative cardiovascular comorbidities and 5-year Framingham Risk Scores (FRS) were assessed to evaluate the relationship between baseline mSASI and cardiovascular risk.

Clinical Associations between mSASI and Cardiovascular Risk

The study stratified patients into three groups by mSASI score: 1 (least severe, n=118), 2 (moderate, n=71), and 3 (most severe, n=20). Those with mSASI scores of 2 or 3 showed significantly higher prevalence of hypertension (51% vs 33%, p=0.011) compared to mSASI 1. Multivariable linear regression analysis identified baseline mSASI (β=4.4; 95% CI 0.04–8.7) and older age (β=1.3; 95% CI 1.0–1.6) as independent predictors of higher FRS, suggesting direct correlation of composite OSA severity with calculated cardiovascular risk.

However, secondary analyses that excluded overlapping components between mSASI and FRS (e.g., age, blood pressure) failed to replicate the association, indicating that the integrated indices may partially reflect shared risk factors rather than independent predictive power of mSASI in isolation.

Comparisons with Traditional Metrics and Other Risk Scores

While the apnea-hypopnea index (AHI) alone remains the most commonly used severity metric, it inadequately considers anatomical and symptomatic heterogeneity affecting cardiovascular risk. The mSASI attempts to bridge this gap by encompassing multi-domain factors relevant to OSA pathophysiology and CV risk.

Recent guidelines on OSA (AASM, 2023) acknowledge limitations of sole reliance on AHI and encourage incorporation of symptom severity and comorbidities in risk assessment. The Framingham Risk Score (FRS), a validated estimator of 5-year cardiovascular events based on traditional CV risk factors, complements OSA-specific indices by quantifying underlying vascular risk independent of sleep parameters.

Methodological Considerations and Research Gaps

The retrospective design of current cohorts and single-center settings limit generalizability. The modest sample size, with fewer patients in the highest severity category (mSASI=3), reduces statistical power for subgroup analyses.

An essential limitation is the substantial overlap of variables integrated in both mSASI and FRS, which confounds independent associations. Future research should explore refined composite metrics that minimize redundancy and leverage biomarker or imaging data representing endothelial function, oxidative stress, or autonomic dysregulation for improved cardiovascular risk prediction.

Furthermore, prospective longitudinal studies are needed to evaluate whether mSASI predicts incident cardiovascular events and whether surgical interventions guided by mSASI improve long-term outcomes.

Expert Commentary

The emergence of mSASI represents an important evolution in personalized OSA severity assessment, recognizing the heterogeneity of the disorder and its cardiovascular sequelae. This approach acknowledges that OSA severity is not solely defined by respiratory event frequency but also by anatomical predisposition, obesity, and symptomatic burden.

Clinically, the mSASI may facilitate identification of high-risk CPAP-intolerant patients who could benefit most from surgical interventions, where standard metrics like AHI fall short. The independent association with Framingham Risk underscores the clinical relevance of integrating multi-dimensional assessment.

However, the attenuation of association in models controlling for overlapping risk factors warrants careful interpretation. The field must advance beyond composite indices to mechanistically informed biomarkers and personalized phenotyping.

Current practice guidelines still prioritize AHI-based criteria and clinical symptom assessments for treatment decisions but increasingly recognize the value of multidimensional indices. Integration into risk stratification algorithms and decision-support tools requires further validation.

Conclusion

The modified sleep apnea severity index (mSASI) offers a promising multidimensional framework for assessing OSA severity and its cardiovascular risk in CPAP-intolerant patients undergoing surgical therapy. Early evidence shows correlation with hypertension prevalence and Framingham Risk Scores beyond AHI alone, but methodological limitations and overlapping variables temper these findings.

Future research directions include prospective multicenter validation, exploration of novel biomarkers to enhance predictive specificity, and assessment of mSASI-guided therapeutic outcomes. Such efforts could refine clinical risk stratification, inform personalized surgical candidacy, and ultimately improve cardiovascular prognosis in OSA patients unable to tolerate CPAP.

References

• Kaki PC, Goldfarb JA, Xu M, Campbell DJ, Molin N, Creighton E, Kaffenberger TM, Boon M, Huntley C. Modified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP-Intolerant OSA Patients. Laryngoscope. 2026 Mar 23;136(7):3262-3270. PMID: 41872124.
• Somers VK, White DP, Amin R, et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement. Circulation. 2008;118(10):1080-1111. PMID: 18725522.
• Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841-858. PMID: 28262680.
• Flemons WW, Buysse D, Redline S, et al. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22(5):667-89. PMID: 10450601.
• Karimi M, Hedner J, Nägga K, et al. Risk stratification by comprehensive evaluation in sleep apnea: beyond the apnea-hypopnea index. Sleep Med Rev. 2020;50:101237. PMID: 32079360.